During metastatic progression, circulating cancer cells become lodged within the microvasculature of end organs, where most die from mechanical deformation. Although this phenomenon was first described over a half-century ago, the mechanisms enabling certain cells to survive this metastasis-suppressive barrier remain unknown. By applying whole-transcriptome RNA-sequencing technology to isogenic cancer cells of differing metastatic capacities, we identified a mutation encoding a truncated form of the pannexin-1 (PANX1) channel, PANX1 , as recurrently enriched in highly metastatic breast cancer cells. PANX1 functions to permit metastatic cell survival during traumatic deformation in the microvasculature by augmenting ATP release from mechanosensitive PANX1 channels activated by membrane stretch. PANX1-mediated ATP release acts as an autocrine suppressor of deformation-induced apoptosis through P2Y-purinergic receptors. Finally, small-molecule therapeutic inhibition of PANX1 channels is found to reduce the efficiency of breast cancer metastasis. These data suggest a molecular basis for metastatic cell survival on microvasculature-induced biomechanical trauma.
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During metastatic progression, circulating cancer cells become lodged within the microvasculature of end organs, where most die from mechanical deformation. Although this phenomenon was first described over a half-century ago, the mechanisms enabling certain cells to survive this metastasis-suppressive barrier remain unknown. By applying whole-transcriptome RNA-sequencing technology to isogenic cancer cells of differing metastatic capacities, we identified a mutation encoding a truncated form of the pannexin-1 (PANX1) channel, PANX1 , as recurrently enriched in highly metastatic breast cancer cells. PANX1 functions to permit metastatic cell survival during traumatic deformation in the microvasculature by augmenting ATP release from mechanosensitive PANX1 channels activated by membrane stretch. PANX1-mediated ATP release acts as an autocrine suppressor of deformation-induced apoptosis through P2Y-purinergic receptors. Finally, small-molecule therapeutic inhibition of PANX1 channels is found to reduce the efficiency of breast cancer metastasis. These data suggest a molecular basis for metastatic cell survival on microvasculature-induced biomechanical trauma.
Primary tumour cells entering the blood stream are rapidly transported away from their site of origin and disseminated throughout the body. These circulating cancer cells eventually land in the microvascular beds of secondary end organs, where they are deformed within capillaries of smaller diameter and lower compliance 1 . This mechanical stress is responsible for the loss of up to greater than 90% of cancer cells entering the small vessels [2] [3] [4] [5] [6] . Despite this barrier to metastatic progression, subsets of cancer cells are able to endure such mechanical stress, thereby maintaining an opportunity to infiltrate the parenchyma of organs and ultimately form lethal metastatic colonies. Although recent work has revealed genes and biological processes regulating steps of metastatic progression [7] [8] [9] [10] [11] [12] , the molecular mechanisms that enable select cancer cells to survive microvascular deformation are not understood. By analysing recurrent alterations in the mutational spectra of in vivo-selected metastatic human breast cancer cells, we have identified extracellular ATP release through pannexin-1 (PANX1) channels as a pro-metastatic signal that permits the survival of cancer cells while they are deformed in the vasculature of metastatic organs.
RESULTS

Identification of mutations enriched in highly metastatic breast cancer cells
Despite great advancements in tumour sequencing technology, it remains to be determined whether mutations exist that function specifically to drive metastasis 13 . This is very likely a consequence of the expansive genetic heterogeneity present in bulk tumour tissue. For instance, low-frequency (<10%) sub-clonal mutations comprise most mutations present in breast tumours 14, 15 . To circumvent this problem, we performed a systematic screen for functional non-synonymous single-nucleotide variants (nSNVs) with allelic frequencies that were recurrently enriched through in vivo selection for metastatic subclones. We reasoned that the discovery and functional characterization of such mutations might reveal molecular signalling pathways not yet known to play a role in metastasis biology. To this end, we performed whole-transcriptomic RNA sequencing (RNA-seq) of in vivo-selected 16, 17 highly metastatic human breast cancer cell sublines, CN-LM1A and MDA-LM2, as well as the CN34 and MDA-MB-231 parental lines from which they were derived (Supplementary Fig. 1a and Supplementary Table 1) . We postulated that the nSNVs most likely to confer a metastatic advantage should be expressed in the transcriptomes of both CN-LM1A and MDA-LM2 sub-lines at allelic frequencies significantly higher than those quantified in their less metastatic parental populations CN34 and MDA-MB-231, respectively. Our discovery framework (see Methods) implicated four missense variants and a single nonsense variant as potential promoters of metastasis ( Fig. 1a and Supplementary Fig. 1b ). The genes bearing the missense nSNVs include the mitochondrial ribosome-binding factor RBFA, the transcription factor REST, the integrin-β1 regulator (e) Time-course measurements of CBX-sensitive ATP release from CN34 parental cells and the CN-LM1A metastatic derivative sub-line pretreated with CBX (500 µM) or PBS for 10 min; n = 4. Error bars, s.e.m., NS, not significant; * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents biological replicates. Experimental results presented are representative and were independently replicated at least two times with two independent cell lines.
A R T I C L E S
KRIT1 and the zinc-finger-containing gene ZSWIM6. The nonsense variant, PANX1 C268T, was significantly enriched in the PANX1 messenger RNA transcripts of the PANX1 ATP channel of both sub-lines. Sanger sequencing of cDNA independently confirmed the enrichment of these mutant alleles in metastatic breast cancer cells (Fig. 1a) . These mutations implicate five genes as potential regulators of breast cancer metastasis.
PANX1
1-89 enhances pannexin-1 channel activity
The therapeutic targeting of proteins expressed on the surface of cancer cells by antibodies such as anti-HER2 (Herceptin) or anti-CD20 (rituximab) have had major impacts on the survival of patients with breast cancer and lymphoma, respectively. As the PANX1 mutation alters a cell-surface channel protein, we reasoned that, if functional, it too might offer potential for therapeutic targeting. Allele-specific RNA-seq ( Supplementary Fig. 1c ) and Sanger sequencing of genomic DNA ( Supplementary Fig. 1d ,e) validated the transcriptomic and genomic enrichment of the PANX1 C268T allele in the highly metastatic derivative sub-lines, respectively. PANX1 encodes the monomeric subunit of a hexameric plasma membrane channel that, when activated, mediates the release of ATP from cells into the extracellular space [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] -a well-established autocrine/paracrine intravascular signalling mechanism 28, 29 . The PANX1 C268T nonsense mutation substitutes a premature termination codon for the glutamine codon at position 90 of the 426-amino-acid PANX1 protein. Before testing this mutation in PANX1 channel activity assays, we wanted to know whether the metastatic human breast cancer cells in which PANX1 C268T was identified express functional PANX1 channels. Indeed, treatment of the CN-LM1A and MDA-LM2 metastatic sub-lines with three established PANX1 inhibitors-probenecid 30, 31 (Prob), carbenoxolone 22, 25, 30, 32, 33 (CBX), or the more potent mimetic peptide 10 Panx1 (Supplementary Fig. 2a ) 22, 26, 30 -significantly reduced extracellular ATP release ( Fig. 1b and Supplementary Fig. 2b,c) , suggesting that highly metastatic breast cancer cells mediate substantial ATP release through PANX1 channels. To determine whether PANX1 alters ATP release through PANX1 channels, we measured extracellular ATP release from cells expressing wild-type PANX1 alone, wild-type PANX1 with PANX1 1-89 , or PANX1 5 BT549 cells transfected with siRNAs against PANX1 or control siRNA; n = 5. Error bars, s.e.m., * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents number of mice in a,b,d,f,g and mouse lungs in c and e. Experiments b-f are representative and were replicated at least two times in independent cell lines. Bioluminescent and histological images are representative of the median.
alone. PANX1-mediated ATP release was quantified by measuring the reduction in ATP release in the presence of CBX (refs 22,25,30,32,33) . When co-expressed with full-length PANX1, PANX1 significantly enhanced the release of ATP through PANX1 channels ( Fig. 1c and Supplementary Fig. 2d ). However, ATP release was not enhanced when PANX1 was expressed alone in PANX1-deficient human cells (Fig. 1c) or in PANX1-null mouse embryonic fibroblasts ( Supplementary Fig. 2e ), suggesting that mutant PANX1 1-89 requires the presence of wild-type full-length PANX1 for its effect and does not homo-oligomerize to form functional ATP release channels. The expression of PANX1 was also sufficient to significantly augment PANX1-mediated ATP release in HCC1806, BT549 and MDA-MB-468-three distinct human breast cancer cell lines harbouring wild-type endogenous PANX1 ( Fig. 1d and Supplementary Fig. 2f,g ). This effect was significantly reduced following knockdown of endogenous wild-type PANX1 ( Fig. 1d and Supplementary Fig. 2h ), further suggesting that PANX1 mediates the enhancement of extracellular ATP release from breast cancer cells specifically through full-length PANX1 channels. Consistent with these findings, highly metastatic CN-LM1A and MDA-LM2 sub-lines secreted nearly fivefold more PANX1-mediated ATP than their less metastatic parental cell populations without expressing higher levels of the PANX1 gene ( Fig. 1e and Supplementary Fig. 2i,j) .
PANX1 channel activity promotes metastatic cell survival in the vasculature
Given these findings, we went on to study whether activated PANX1 channels play a role in cancer metastasis. We first investigated whether PANX1 channels are activated in vivo. To address this, we injected breast cancer cells expressing plasma-membrane-anchored extracellular luciferase into the venous circulation of mice, and quantified the extracellular ATP released from cancer cells in vivo. Five minutes after venous injection, we observed significant extracellular ATP bioluminescent signal detected in the lungs of mice, which was attenuated following pharmacological pretreatment of cells with the PANX1 inhibitor CBX (Fig. 2a) . To determine whether the observed early activation of PANX1 channels is necessary for efficient metastasis, we acutely blocked PANX1 channels by pre-incubating CN-LM1A and MDA-LM2 cells with 10 Panx1 or its corresponding scrambled peptide and assessed the cells' metastatic activity through (e) Quantification of viable, trypan blue-negative, CN-LM1A cells after 1 h incubation in extremely hypotonic (12.5% PBS) solution in the presence of scrambled peptide (100 µM), 10 Panx1 peptide (100 µM) or 10 Panx1 peptide (100 µM) and 100 µM ATP; n = 4. (f) Quantification of viable, trypan blue-negative, MDA-LM2 cells after 1 h incubation in extremely hypotonic (12.5% PBS) solution in the presence of scrambled peptide (100 µM), 10 Panx1 peptide (100 µM) or 10 Panx1 peptide (100 µM) and 100 µM ATP; n = 4. (g) Quantification of viable, trypan blue-negative MDA-LM2 cells with 30 min Boyden chamber centrifugation (1,243g) after cells were pretreated for 10 min with 500 µM CBX or PBS; n = 4. Error bars, s.e.m., * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents biological replicates. Experiments b-g are representative and were replicated at least two times with two independent cell lines.
tail-vein lung colonization assays. This acute (30 min) inhibition of PANX1 significantly inhibited metastasis as evidenced by reductions in metastatic signal at early time points that persisted at 6-week endpoints (Fig. 2b,c and Supplementary Fig. 2k,l) , suggesting that PANX1 channel activity increases the metastatic capacity of human breast cancer cells.
To confirm that PANX1 inhibition blunts early metastatic dissemination, we performed tail-vein injections of CN-LM1A and MDA-LM2 metastatic cells pretreated with 10 Panx1 and quantified lung bioluminescence daily, over three days ( Fig. 2d and Supplementary Fig. 3a ). Consistent with a role for activated PANX1 channels in metastatic dissemination, inhibition of PANX1 led to a significant decrease in lung bioluminescence as early as day one ( Fig. 2d and Supplementary Fig. 3a ). Histological examination of lungs from these mice also revealed a reduction in the number of disseminated breast cancer cells ( Fig. 2e and Supplementary  Fig. 3b ). The acute impact of PANX1 channel inhibition on cancer cell bioluminescence in the lung suggested a block in metastatic progression in the vasculature. In support of this, PANX1 blockade did not inhibit proliferation, invasion, transendothelial migration or anchorage-independent cell survival capacity ( Supplementary  Fig. 3c-g ). We therefore reasoned that PANX1 inhibition might increase cell death within the microvasculature. To test this, we performed tail-vein injections of CN-LM1A and MDA-LM2 metastatic cells preincubated with 10 Panx1 or scrambled peptides and quantified in vivo caspase activity using a luciferase-based reporter. In support of enhanced intravascular cell death, in vivo caspase activity was significantly augmented following PANX1 inhibition at early time points (3 and 6 h) post-injection ( Fig. 2f and Supplementary  Fig. 3h )-well before monocyte recruitment (24 h; ref. 34) or cancer cell extravasation (48 h; refs 34,35) occur. Consistent with these findings, acute short interfering RNA (siRNA)-mediated knockdown of PANX1 channels in the independent metastatic breast cancer cell line BT549 significantly decreased cancer cell lung bioluminescence at 8-h post venous injection (Fig. 2g) , further supporting the role of PANX1 channels in promoting microvascular survival during metastatic dissemination.
ATP release from mechanosensitive PANX1 channels promotes metastatic cell survival during intravascular deformation through purinergic signalling Confocal microscopy revealed that, at the time when PANX1 activity was found to promote survival (3 h post-injection), cancer cells were confined within the pulmonary vasculature and many had become morphologically elongated in small blood vessels (Fig. 3a) . Consistent with quantitative in vivo caspase measurements, a number of these intravascular cancer cells exhibited activated caspase immunoreactivity (Fig. 3a) . Of the many mechanisms responsible for the inefficiency of metastasis, intravascular death is responsible for the loss of up to greater than 90% of the cancer cells entering the microvasculature of secondary organs [2] [3] [4] [5] [6] . Considering that caspasepositive breast cancer cells were substantially elongated in the small lung vessels soon after injection (Fig. 3a) , and that PANX1 is a mechanosensitive channel that opens during plasma membrane stretch [18] [19] [20] [21] , we wondered whether PANX1 activation during cancer cell deformation in the vasculature might underlie its observed role in early cancer cell survival. Hypotonic cell swelling-an established perturbation that imparts plasma membrane stretch in a well-controlled manner 6, [19] [20] [21] 36 -significantly increased the amplitude of PANX1-mediated ATP release in CN-LM1A and MDA-LM2 breast cancer cells (Fig. 3b) . Accordingly, we found CN-LM1A and MDA-LM2 cells to be significantly more resistant to lethal hypotonic stretch relative to their parental population (Fig. 3c,d ). We then tested the role of PANX1 activity in promoting survival during cell deformation by hypotonically stretching CN-LM1A and MDA-LM2 cells in the presence of the 10 Panx1 inhibitor or scrambled control peptides. The number of viable cancer cells remaining after incubation in hypotonic solution was significantly reduced when cells were subjected to PANX1 channel inhibition (Fig. 3e,f) . Moreover, PANX1 inhibition also reduced cell survival after centrifugal stretch ( Fig. 3g and Supplementary Fig. 4a ). Importantly, cell viability was fully rescued in the PANX1-inhibited cells through addition of extracellular ATP (Fig. 3e,f) . These data suggest that ATP signalling at the cell surface mediates the observed survival phenotype.
As intravascular purinergic signalling at the plasma membrane could affect multiple cellular processes 28 , we investigated whether ATP release through PANX1 channels could be responsible for its metastasis-enhancing effects. To address this, we expressed CD39, a plasma-membrane-anchored extracellular ATP hydrolase, in CN-LM1A cells and tested their ability to metastasize. CD39 expression, which substantially depleted extracellular ATP at the plasma membrane ( Supplementary Fig. 4b ), significantly reduced metastatic lung signals at early (Supplementary Fig. 4c ) and late ( Fig. 4a) time points, and substantially reduced the number of metastatic foci in the lungs (Fig. 4b) . Consistent with ATP being necessary for cancer cell survival in the vasculature, CN-LM1A and MDA-LM2 lung bioluminescence was significantly reduced 6 h after intravenous co-injection of cells with apyrase, a potent extracellular ATP hydrolase 22, 37 ( Fig. 4c,d ). Additionally, the viability of CN-LM1A and MDA-LM2 cells was markedly reduced following their exposure to hypotonic solution supplemented with suramin ( Fig. 4e,f) a broad-spectrum antagonist of ATP-binding P2y-purinergic receptors 38 (P2yRs), suggesting that ATP release stimulated by plasma membrane stretch activates P2yRs whose signalling protects cancer cells from lethal mechanical injury. These data reveal a role for extracellular ATP release through mechanosensitive PANX1 channels as a cancer cell-autonomous survival signal during traumatic deformation of the plasma membrane.
Mutationally enhanced PANX1-mediated ATP release drives metastatic efficiency
To test PANX1 activity in gain-of-function experiments, we utilized the expression of the PANX1-activating mutation, PANX1 , because metastatic breast cancer cells did not tolerate the supraphysiological overexpression of wild-type PANX1 channels; presumably secondary to critical losses of ATP. We first wanted to further characterize the molecular association between PANX1
1-89 and full-length subunits of PANX1 channels. As PANX1 homo-oligomerizes to form functional channels 39 and metastatic cells express both wild-type and mutant PANX1, we reasoned that PANX1
1-89 interacts with full-length PANX1. In support of this, we detected prominent co-localization of full-length PANX1 and PANX1
1-89 at the plasma membrane ( Fig. 4g ). To directly test whether PANX1
1-89 interacts with full-length PANX1, we performed reciprocal in vitro co-immunoprecipitation experiments that revealed PANX1 to associate with full-length PANX1 ( Supplementary Fig. 4d ,e). To confirm this interaction, we tested whether PANX complexes with full-length PANX1 in live cells by performing crosslinking of cellular proteins in culture. Coimmunoprecipitation of PANX1 1-89 from protein-crosslinked cells revealed the mutant protein to be in close association with wildtype PANX1 in vivo ( Fig. 4h and Supplementary Fig. 4f,g ). We also found that the increase in ATP release mediated by PANX1 1-89 was independent of caspase signalling, a known activator of PANX1 channel activity in pre-apoptotic cells 22, 40 , as mutation of the caspase cleavage site in PANX1 did not impair its ATP release enhancement ( Supplementary Fig. 4h ). Interestingly, PANX1
1-89 lost the ability to augment ATP release when co-expressed with PANX1
1-297 , a mutant lacking the intracellular carboxy-terminal domain that has been shown to interact with the pore of the channel to impede ATP release 22, 40 ( Fig. 4i) , suggesting that this domain may be required for channel activation by PANX1 . These findings reveal PANX1 1-89 to be an activator of PANX1 channels in breast cancer and implicate the amino-terminal domain of PANX1 as a positive regulator of channel activation in metastatic breast cancer cells.
We then tested whether PANX1 1-89 is sufficient to promote metastasis in cancer cells expressing wild-type PANX1 channels. Indeed, 1-89 -mRFP (magenta). Co-localization at the plasma membrane is shown by channel overlay (white). Nuclear (nuc) DAPI stain is indicated. Arrowheads indicate PANX1-EGFP and PANX1
1-89 -mRFP1 co-localization at the plasma membrane. Scale bar, 5 µm. (h) Co-immunoprecipitation of PANX1
1-89 -RFP from protein-crosslinked (2 mM dithiobis(succinimidyl propionate)) HEK293T cells expressing PANX1-EGFP, PANX1-EGFP and PANX1
1-89 -mRFP, or PANX1 1-89 -mRFP. Anti-GFP antibody was used to detect the wild-type PANX1 in complex with mutant PANX1 . Molecular weights are indicated. (i) Quantification of ATP release from HEK293T cells transfected with 5 µg wild-type PANX1 (n = 8), 5 µg wild-type PANX1 and 2.5 µg PANX1 (n = 9), 5 µg C-terminus-deleted PANX1 1-297 (n = 11) or 5 µg PANX1 1-297 and 2.5 µg PANX1 1-89 (n = 12). Error bars, s.e.m., NS, not significant, * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents number of mice in a,c,d, number of mouse lungs in b, and biological replicates in e,f,i. Experiments c-f are representative and were replicated at least two times with independent cell lines. Bioluminescent and histological images are representative of the median. Unprocessed original scans of blots are shown in Supplementary Fig. 6 .
expressing PANX1
1-89 in MDA-MB-468 and HCC1806 cells, which do not express mutant PANX1 endogenously, led to significantly increased metastatic dissemination in orthotopic (Fig. 5a,b ) and tail-vein (Fig. 5c,d ) metastasis assays. These experiments also revealed the nonorgan-specific pro-metastatic effect of PANX1 , as cells expressing PANX1 exhibited an enhanced capacity to spread systemically (Fig. 5b,c) and to colonize distant organs such as the lung, liver and bone (Fig. 5d) . We next sought to determine the impact of PANX1 on intravascular metastatic cell survival. Expression of PANX1 in BT549 and MDA-MB-468 cells was sufficient to significantly increase cancer cell bioluminescence in the lung 18 h after injection ( Fig. 5e and Supplementary Fig. 5a ) and decrease in vivo cell death (activatedcaspase signal) at 3 and 6 h after injection ( Fig. 5f and Supplementary Fig. 5b ). PANX1
1-89 expression also significantly enhanced the survival of BT549 and MDA-MB-468 cells during hypotonic stretch ( Fig. 5g and Supplementary Fig. 5c ). Moreover, the addition of apyrase to PANX1 1-89 -expressing cells in hypotonic solution completely abrogated the survival advantage afforded by PANX1 1-89 expression ( Fig. 5g and Supplementary Fig. 5c ), suggesting that extracellular ATP is responsible for the enhanced viability resulting from mutant PANX1 expression. These data reveal that PANX1
1-89 -induced PANX1 channel activity enhances the efficiency of metastasis by promoting metastatic breast cancer cell survival during physical deformation.
Pharmacological inhibition of PANX1 channels reduces breast cancer metastasis
Finally, we investigated whether pharmacological inhibition of activated PANX1 channels on metastatic cells could suppress 1-89 or a control vector after 1 h extreme hypotonic (12.5% PBS) stretch in the presence of succinate buffer or apyrase (2 U ml −1 ); n = 3. Error bars, s.e.m., * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents number of mouse lungs in a, number of mice in b,c,e,f, and biological replicates in g. Orthotopic experiments were replicated in two independent triple-negative cell human breast cancer cell lines. Experiments e-g are representative and were replicated at least two times in at least two independent cell lines. Bioluminescent and histological images are representative of the median. metastatic progression. CN-LM1A cells pretreated with CBX, a PANX1 channel inhibitor approved for the treatment of gastroesophageal reflux disease in the UK, exhibited markedly reduced lung-metastatic activity ( Supplementary Fig. 5d,e) . To better assess the clinical potential of this therapy, we treated mice with two distinct CBX regimens before introducing metastatic breast cancer cells into the circulation (Fig. 6a) . We found that seven days of CBX therapy significantly inhibited the ability of highly metastatic MDA-LM2 cells to colonize the lungs (Fig. 6b,c) . Importantly, this treatment was well tolerated and did not impact body weight (Supplementary Fig. 5f ). Strikingly, reducing this treatment to two doses of CBX within 24 h of cancer cell injection significantly reduced the number of highly metastatic CN-LM1A cells in the lungs at as early as 24 h (Fig. 6d,e) as well as lung-metastatic colonization at four weeks (Fig. 6f,g and Supplementary Fig. 5g ). These data suggest that pharmacological PANX1 inhibition could have the potential to blunt the development of new distant metastases in patients with metastatic primary tumours.
DISCUSSION
By applying whole-transcriptome sequencing analyses to isogenic cancer cells of differing metastatic capacities, we have identified a mutation in a channel that promotes metastatic progression. This study illustrates how the identification of a sub-clonal mutation that is recurrently enriched in the transcriptomes of highly metastatic human cancer cells can serve as a molecular clue for uncovering biological mechanisms that regulate a complex step of cancer metastasis. The identification of a PANX1 channel-activating mutation, PANX1
1-89 , led to our finding that PANX1 channel activity can promote the metastasis of certain breast cancer cells by improving their ability to withstand traumatic deformation in the microvasculature of target organs. Although the extent to which PANX1 activity plays a role in human cancer metastasis remains unknown, we propose a working model based on our findings whereby augmented ATP release through mechanosensitive PANX1 channels results in the cell-autonomous enhancement of cancer cell survival during microvasculature-induced plasma membrane stretch-an important i.p. CBX (n = 9) or an equivalent volume of PBS (n = 10) at 19 and 2 h before cancer cell injection. (g) Quantification of the number of metastatic foci at 4 weeks from H&E-stained lungs; n = 10 (vehicle), n = 9 (CBX). Error bars, s.e.m., * , P < 0.05; * * , P < 0.01; * * * , P < 0.001 by a one-tailed Student's t-test. n represents number of mice in b,d,f, number of mouse lungs in c,e,g. Therapeutic PANX1 inhibition experiments were performed using two independent triple-negative breast cancer cell lines. Bioluminescent and histological images are representative of the median.
barrier to metastatic progression (Fig. 7) . Our work suggests that ATP released by PANX1 channels mediates this effect through purinergic receptors on the cell surface, which have been implicated in survival signalling during deformation-induced injury 37 . Although we have identified ATP release and its action through purinergic P2Y receptor(s) as mediating the survival effects during breast cancer cell stretch, the identity of the specific purinergic receptor(s) remains unknown. Systematic investigation of P2Y receptors involved in PANX1-mediated ATP-dependent mechanical survival should reveal the P2Y receptor(s) specifically responsible for mediating the pro-survival effects and, in turn, identify an additional putative therapeutic target for the prevention of distant metastasis. Moreover, future studies will uncover the signal transduction pathways and their link to pro-survival genes that mediate cell survival by this pathway.
We have found that the truncated PANX1 1-89 protein augments ATP release from cells. The ability of PANX1 to augment ATP release requires full-length wild-type PANX1 expression. The molecular/structural basis for the suggested interaction between PANX1 1-89 and full-length PANX1 remains to be characterized. Crystallographic studies of PANX1 in association with full-length PANX1 should be quite illuminating with respect to the mechanism of enhanced PANX1 channel opening. One potential mechanism by which PANX1
1-89 augments ATP release through PANX1 channels might be through the loss of the autoinhibitory C-terminal domain that is lacking in the PANX1 1-89 mutation 40 . It is possible that other truncating mutations lacking the PANX1 C-terminal domain or missense mutations interfering with the tail-to-pore interaction, could also lead to increased channel activity. However, because high PANX1 activity can be detrimental to cancer cell proliferation, sequencing of bulk tumours may underestimate the prevalence of channel-activating mutations that may drive metastatic progression in patients.
We have shown that enhanced ATP release through PANX1 can promote breast cancer cell survival in the context of mechanical deformation. It is also possible that ATP or breakdown products of ATP, such as ADP, AMP or adenosine, could also regulate metastatic progression at later time points by modulating the microenvironment through effects on immune cell effectors. PANX1 channel opening is herein identified as a potential druggable target whose therapeutic inhibition may reduce the development of clinical metastases. Patients at high risk for relapse that may particularly benefit from PANX1 blockade therapy include those undergoing diagnostic or therapeutic procedures that may cause cancer cells to enter the vasculature during mechanical tumour perturbation. For example, fine-needle aspiration of human breast tumours has been shown to cause shedding of cancer cells into the bloodstream 41 , which are rapidly transported to distant sites. Likewise, experiments in mice have found that operative trauma during surgical dissection can lead to haematogenous dissemination and subsequent metastasis 42, 43 . Therapeutic inhibition of PANX1 with CBX-a drug with proven safety in humans-has the potential to reduce the development of distant metastases in such cases. CBX could also represent a starting point for the development of more potent PANX1 inhibitors through medicinal chemistry. It will be important for future studies to examine whether augmented PANX1 activity, as a consequence of activating mutations or increased gene expression, plays a broader role in promoting the metastasis of additional tumour types.
METHODS
Methods and any associated references are available in the online version of the paper. and MDA-LM2, were generated and propagated as previously described 16, 44 . HEK293T, PANX1-null mouse embryonic fibroblasts (MEFs), and MDA-MB-468 cells were cultured in DMEM-based media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and fungizone. BT549 and HCC1806 lines were cultured in RPMI-based media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and fungizone. Cells were periodically tested for mycoplasma contamination. CN34, MDA-MB-231, CN-LM1A and MDA-LM2 cell lines were authenticated by RNA-seq profiling. All transfections were performed using Lipofectamine 2000 (Life Technologies).
RNA sequencing, read alignment, allele frequency quantification and SNV calling. Total RNA was extracted using the MiRvana kit (Ambion) and reverse transcribed using the cDNA First-Strand Synthesis kit (Life Technologies). For whole-transcriptome sequencing, cDNA libraries were generated using the mRNA Sequencing Sample Preparation Kit (Illumina, 2009) according to the manufacturer's instructions and sequencing-by-synthesis was performed using the GAIIx sequencer (Illumina). For read alignment, the quality of the reads generated by highthroughput sequencing was first examined using the FASTX toolkit (http:// hannonlab.cshl.edu/fastx_toolkit). The reads were then trimmed and filtered by quality and aligned against the human genome (release hg18) using the TopHat aligner 45 , which builds exon models de novo from the RNA-seq data and aligns reads across splice junctions. PCR duplicates that might interfere with SNV calling were removed. A statistical framework was then implemented to identify SNVs from the read alignments on the basis of the assumption that biological variations will be found in a significant number of reads, although non-biological variations will not. A Poisson-binomial distribution 46 was used to calculate the P values of significance, taking into account the total number of reads at each genomic position, number of reads with mismatches, and the error rate at each sequencing cycle (for example, typically the sequencing error is higher during later stages of sequencing). P values were corrected for multiple hypotheses using the Benjamini-Hochberg method 47 and the false discovery rate was controlled to 1%. SNVs identified in less than 10 unique reads were removed from further analysis. The SNVs were also filtered to remove known single-nucleotide polymorphisms (SNPs) reported in dbSNP (v130) and annotated with our in-house programs (T.D.S. and O.E., in preparation). To minimize the false-positive rate and enable subsequent statistical analyses, we sequenced biological replicates of each cell line. Low-confidence mutations were excluded by removing known polymorphisms, low-coverage (<10×) nSNVs and any nSNV not detected in both biological RNA-seq replicates of each cell line. To identify nSNVs significantly enriched during metastatic selection, we quantified the differences in nSNV allelic frequencies between the highly metastatic sub-lines and their respective poorly metastatic parental lines. Metastasis-enriched nSNVs were defined as those that exhibited an increase in allelic frequency over the four rounds of RNA-seq and met the criteria for significance (P < 0.05, q ≤ 0.25) by a one-tailed Student's t-test ( Supplementary Fig. 1a,b) . Two additional computational algorithms (SNVmix; ref. 48 and VarScan; ref. 49) independently validated these methods. SNV allelic ratios were calculated by dividing the number of unique reads containing a given variant by the total number of unique reads at each position 50 . Amino-acid substitutions resulting from the nSNVs were ranked by the likelihood of being nonneutral using the computational tool PolyPhen-2 (http://genetics.bwh.harvard.edu/ pph2; ref.
51).
Allele-specific RNA-seq. Two-step PCR reactions of the PANX1 C268T allele in biological triplicates of each cell line were performed using the barcoded primers listed in Supplementary Table 2 . PCR amplicons were then sequenced using the HiSeq2000 (Illumina) platform. Position-specific quantification of each allele was performed and used to calculate the PANX1 C268T allelic frequency of each cell line replicate. Animal studies. All animal work was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at The Rockefeller University. Seven-to eight-week-old age-matched female NOD/SCID mice were used for breast cancer tail-vein lung colonization and systemic metastatic colonization assays 17, 44 . PANX1-null mice (Shestopalov laboratory, University of Miami, USA) were bred for the generation PANX1-null MEFs at embryonic day 14 (E14). For the in vitro PANX1 inhibition metastasis assays, 1 × 10 5 LM1A or 4 × 10 4 LM2 cells in 100 µl were incubated for 30 min with either 100 µM 10 Panx1 (Tocris), 100 µM scrambled peptide (Tocris), 500 µM CBX (Sigma-Aldrich) or an equivalent volume of PBS vehicle and injected intravenously into the lateral tail vein. For the in vivo therapeutic PANX1 inhibition metastasis assays, mice were weighed, treated with CBX or an equivalent volume of PBS by intraperitoneal injections at the indicated times and doses, and then tail vein injected with 1 × 10 5 LM1A or 4 × 10 4 LM2 cells. For the PANX1 extracellular ATP release assays, 1 × 10 5 MDA-LM2 cells expressing plasma-membrane-anchored luciferase 52 (LM2-pmeLUC) were preincubated with CBX (500 µM) or an equivalent volume of PBS vehicle and injected into seven-week-old age-matched female FVB/NJ mice. For orthotopic metastasis assays, two primary tumours per NSG mouse were generated through bilateral injections of 2.5 × 10 5 MDA-MB-468 or 5.0 × 10 5 HCC1806 breast cancer cells into the lower mammary fat pads. The resulting tumours were measured every three days, size-matched, extracted at 100 mm 3 and metastatic cell dissemination and colonization was non-invasively assayed through bioluminescence imaging as previously described 17 . For the long-term metastasis assays involving extracellular ATP depletion, 1 × 10 6 CN-LM1A cells, expressing the plasma-membrane-anchored extracellular ATP hydrolase CD39 or control vector, were injected into the lateral tail vein of NOD scid mice. For the acute extracellular ATP depletion assays, cells were preincubated with apyrase (2 U ml −1 ; NEB) or an equivalent volume of succinate buffer control and injected into seven-week-old age-matched female FVB/NJ mice. For the truncated PANX1 in vivo metastasis assays, 5 × 10 5 cells per 100 µl PBS were introduced intravenously through the tail vein (MDA-MB-468 and BT549). Caspase activity was measured in vivo through retro-orbital injections of 0.75 mg of VivoGlo Caspase 3/7 Substrate (Z-DEVD-Aminoluciferin Sodium Salt) (Promega) 53 per mouse.
Generation of PANX1-null MEFs.
MEFs from E14 PANX1-null embryos were generated as previously described 54 .
Generation of retrovirus and stable overexpression cells. Generation of retroviral-overexpressing cells was performed as previously described 17, 44, 55 . Primers used to generate overexpression constructs are listed in Supplementary Table 2 . C-terminal fluorescent protein-tagged PANX1 and PANX1 were cloned into the respective pcDNA3-EGFP and pcDNA3-mRFP1 vectors with a GRPLE linker. Plasma-membrane-anchored extracellular luciferase was cloned as previously described 52 . CD39 (clone 5762493, Open Biosystems) was stably expressed using the lentiviral pLenti vector system. For bioluminescent tracking of MDA-MB-468, BT549 and HCC1806 cancer lines, cells were labelled with a triple-fusion protein reporter construct as previously described 17 .
siRNA-mediated full-length-PANX1-specific messenger RNA knockdown.
siRNAs were transfected into HCC1806 cells using Lipofectamine reagent according to the manufacturer's protocol. Forty-eight hours after transfection, the cellular RNA was extracted and full-length PANX1 mRNA levels were quantified as described previously 17 . At 96 hours after transfection, the cells were subjected to extracellular ATP release assays as described below. siRNA specifically designed to target endogenous full-length PANX1 mRNA without interfering with PANX1 1-89 overexpression was purchased from Life Technologies (ID: 134470, siRNA_A) and Thermo Scientific (custom siRNA sequence: 5 -AGGAAGCA CCUGAGAGUAUU-3 , siRNA_B). BLOCK-iT control siRNAs were obtained from Invitrogen.
Analysis of mRNA expression. Expression of mRNA was quantified as described previously 17 . Primers can be found in Supplementary Table 2 .
Immunofluorescence and confocal microscopy. Cells expressing fluorescently tagged proteins were fixed in 4% paraformaldehyde, stained with DAPI (Roche), mounted using ProLong Gold Antifade reagent (Life Technologies), and imaged using the Leica TCS SP5 II system.
Immunoprecipitation and immunoblotting. Cellular lysates were prepared
by lysing cells (10-40 million) overnight in ice-cold RIPA buffer containing protease and phosphatase inhibitors (Roche). The next day, cellular debris was removed by centrifugation (12,396g ) for 20 min at 4 • C. A 50 µl slurry of anti-FLAG M2 Magnetic Beads (Sigma-Aldrich) was added to the supernatant and rocked for 4 h at 4 • C. The beads were then washed three times with icecold lysis buffer. The immunoprecipitated proteins were eluted by denaturation in Laemmli buffer at 95 • C for 5 min, separated using SD-PAGE, transferred to a PVDF membrane (Pierce), blocked and probed using a primary antibody to the N terminus of PANX1 (1:1,000; ZMD.695 from Life Technologies), which has not been validated specifically for the detection of PANX1 . Bound antibodies were chemiluminescently detected using horseradish-peroxidaseconjugated secondary antibodies (1:10,000), ECL Western Blotting Substrate (Pierce) and the SRX-101A (Konica Minolta) developer, according to the manufacturer's instructions.
Protein crosslinking immunoprecipitation and immunoblotting.
Dithiobis(succinimidyl propionate) was dissolved in anhydrous dimethylsulphoxide, diluted in PBS to formulate crosslinking solutions at the concentrations indicated, and used to crosslink cells in culture according to the manufacturer's instructions (Pierce). Crosslinked cells were then washed twice in PBS and lysed using ice-cold RIPA buffer supplemented with protease and phosphatase inhibitors (Roche). Lysates were collected by cell scraping, sonicated and rotated at 4 • C for 4-12 h. Cellular debris was removed by centrifugation (12,396g ) for 20 min at 4 • C. Protein concentrations were measured using the BCA protein assay (Pierce). For immunoprecipitation of crosslinked proteins, a 50 µl slurry of anti-RFP Magnetic Beads (MBL International) was added to 200 µg protein lysates diluted in 750 µl Co-IP lysis buffer (Thermo Scientific) and rocked for 4 h at 4 • C. The beads were then washed three times in Co-IP lysis buffer, resuspended in Non-Reducing Lane Marker Sample Buffer (Thermo Scientific), boiled at 95 • C for 5 min, and separated using SDS-PAGE on a Novex 3-8% Tris-Acetate gel (Life Technologies). For crosslinked PANX1 complex immunoblotting, primary antibodies against the N terminus of PANX1 (1:100; ZMD.695 from Life Technologies), GFP (1:1,000, ab290 from Abcam) and RFP (1:1,000; biotin conjugated ab34771 from Abcam) were used. Bound antibodies were chemiluminescently detected using horseradish-peroxidase-conjugated secondary antibodies (1:10,000), ECL Western Blotting Substrate (Pierce) and the SRX-101A (Konica Minolta) developer, according to the manufacturer's instructions.
ATP release assays. Cells were seeded in quadruplicate at 100,000-200,000 cells per well in 24-well plates and grown overnight. Each well was then washed with 200 µl PBS. For PANX1 inhibition, cells were incubated at room temperature for 10 min in PBS supplemented with one of the following reagents: CBX (500 µM), probenecid (2 mM; Life Technologies), 10 Panx1 (100 µM) or an equivalent dose of the appropriate vehicle control (100% PBS or scrambled peptide). The wash or pretreatment solution was then aspirated, replaced with 200 µM fresh 100% PBS or 70% PBS (hypotonic stretch assays) for the indicated times, collected and transferred to microcentrifuge tubes, and then spun at 86g for 2 min at room temperature. Supernatants were transferred to 96-well plates and ATP was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer's instructions. For hypotonic stretch assays, the numbers of viable cells remaining post-stretch were counted for each treatment condition to rule out the contribution of cell lysis to extracellular ATP levels.
Histology and immunofluorescence.
For histological quantification of single breast cancer cells, mouse lungs were extracted at one and three days post cancer cell injection. By administering solutions through the heart and trachea, lungs were perfused and fixed with PBS and 4% paraformaldehyde, respectively. Slices were mounted using ProLong Gold Antifade Reagent (Life Technologies). For histological quantification of metastatic foci, mouse lungs were extracted at the indicated time points, perfused and fixed as above, and sent out for sectioning and haematoxylin and eosin staining (Histoserv). Quantification of cells and metastatic foci from histological step sections was performed in a blinded manner. Immunohistochemical staining for human vimentin (1:20, clone V9, Vector Laboratories) was performed on paraffin-embedded sections and visualized with Vectastain ABC kit (PK-6012) and DAB chromagen (SK-4105, Vector Laboratories). Vimentin-positive macroscopic nodules were counted for experimental analysis.
For endothelial labelling, 100 mg of biotinylated lectin dissolved in PBS was injected retro-orbitally and allowed to circulate for 5 min before fixation. Mice were subsequently euthanized, and their lungs were extracted without perfusion and fixed in 4% paraformaldehyde overnight. For immunofluorescence, frozen lung sections (10 µm thick) were stained with antibodies against human vimentin (1:40, clone V9, Vector Laboratories) and cleaved caspase-3 (1:2,000, clone 5A1E, Cell Signaling Technology). Primary antibodies were visualized with Alexa Fluor Dye-conjugated secondary antibodies (1:200, Life Technologies.) Stained sections were mounted using ProLong Gold Antifade Reagent (Life Technologies). Images were obtained using a Zeiss scanning laser confocal microscope (LSM 510).
Hypotonic deformation cell viability assays. Cells were seeded in quadruplicate at 100,000 cells per well in 24-well plates and grown overnight. When comparing wild-type and mutant PANX1-expressing cells, replicate plates of cells were counted at the time of the assay for normalization. Each well was then washed once with 200 µl 100% PBS. For PANX1 inhibition, cells were incubated with 100 µM 10 Panx1 or scrambled peptides for 10 min in 100% PBS. The wash or pretreatment solution was then aspirated, and the cells were stretched in 200 µl hypotonic solution (12.5% PBS) supplemented with the indicated reagents or vehicle controls for the times indicated. For ATP rescue experiments, 100 µM ATP (NEB) was added to the 10 Panx1 hypotonic solution, and an equivalent volume of water was added to the control hypotonic solution. For pan-P2yR inhibition experiments, suramin (50 µM; Sigma-Aldrich) or water vehicle control was added to the pretreatment solution. For ATP depletion experiments, apyrase (2 U ml −1 ) or an equivalent volume of succinate buffer control was added to the hypotonic solution. After deformation, the cells were gently washed twice with 100% PBS, trypsinized, stained with trypan blue (Sigma-Aldrich) and the remaining viable cells were quantified.
Centrifugal deformation cell viability assays. Cells were pretreated with CBX (500 µM) or PBS for 10 min in suspension, then washed and seeded in quadruplicate at 100,000 cells per Boyden chamber in fresh DMEM-based media. The chambers were placed in 24-well plates and centrifuged for 30 min at 1,243g . Viable cells were stained with trypan blue (Sigma-Aldrich) and quantified.
Cancer cell proliferation. For molecular PANX1 inhibition assays, 5 × 10 3 cancer cells overexpressing either the autoinhibitory C-terminal domain or control vector were seeded in quadruplicate in a 96-well plate in a 100 µl volume of DMEMbased media containing 10% FBS. At days 0, 3 and 5, cells were trypsinized and viable cells were counted using a haemocytometer. Proliferation counts were normalized to day 0. For peptide inhibition proliferation assays, cancer cells were pretreated with 100 µM 10 Panx1 peptide or vehicle for 15 min and seeded into 24-well plates (25,000 cells per well) under the same conditions as pretreatment. After 24 h, cancer cells were trypsinized and viable cells were counted using a haemocytometer.
Invasion assays. Invasion assays were performed as previously described 44 . Briefly, serum-starved sub-lines were pretreated for 15 min with 100 µM of 10 Panx1 peptide or scrambled peptide in 0.2% FBS DMEM-based media, seeded onto Transwell invasion chambers (BD Biosciences) under the same treatment conditions and incubated for 18-20 h. Cells that had invaded were counted in five fields per insert and then quantified using ImageJ.
Transendothelial migration assays.
Transendothelial migration assays were performed as previously described 44 . Briefly, serum-starved Cell Tracker Green CMFDA-labelled (Life Technologies) MDA-LM2 cells were pretreated for 15 min with 100 µM of 10 Panx1 peptide or scrambled peptide in 0.2% FBS DMEM-based media, seeded on a monolayer of HUVEC cells under the same treatment conditions (50,000 cells per well) and incubated for 18 h. Migrated cells were counted in five fields per insert and then quantified using ImageJ.
Anchorage-independent survival. Cancer cells (5,000 cells per well) were seeded in quadruplicate on 96-well Ultra-Low Attachment Surface plates (Corning) in the presence of 100 µM of 10 Panx1 peptide or scrambled peptide in 10% FBS DMEMbased media and incubated for 36 h. Cell suspensions were then transferred to microcentrifuge tubes, isolated by centrifugation (86g ) for 5 min, trypsinized and counted using a haemocytometer.
Statistics and representative images.
No statistical methods were used to predetermine sample size. The experiments were not randomized and, other than histological nodule and single-cell quantification, the investigators were not blinded to allocation during experiments and outcome assessment. For all animal studies, discrepancies between n for each data set are the result of death, illness or technical challenges unrelated to the experimental conditions being compared. No randomization or blinding was used for the animal studies. For in vitro experiments, differences in n are due to technical issues during experimental setup or implementation and are unrelated to the experimental outcomes. Exclusion criteria for all studies were pre-established. The statistical tests used to compare experimental samples and cohorts are well established and previously described. One-tailed Student's t-test is the most common statistical analysis implemented in this study. To minimize unrecognized assumptions during data analysis, we often used independent statistical methods for individual experiments. All experimental results presented with representative images, as defined in the figure legends, have been replicated at least two times. Bioluminescent and histological images are representative of the median. with Flag-tagged full-length PANX1 . The multiple bands representing full-length PANX1 represent the previously described glycosylated forms of PANX1. e, Co-immunoprecipitation of PANX1 1-89 -Flag from HEK293T cells co-transfected with full-length PANX1 . Anti-PANX1 N-terminal antibody was used to detect the associated PANX1 species. The multiple full-length PANX1 bands represent the previously described glycosylated forms of PANX1. The input lysates were immunoblotted for PANX1. f, Increasing concentrations of DSP (dithiobis[succinimidyl propionate]) crosslinker were applied to HEK293T cells expressing Flag-tagged PANX1 prior to lysis. PANX1 complexes were detected using anti-FLAG M2 antibody. g, Anti-PANX1 and anti-RFP immunoblotting of DSP crosslinked lysates from HEK293T cells expressing PANX1-EGFP, PANX1-EGFP and PANX1 1-89 -mRFP or PANX1 1-89 -mRFP. Molecular weights are indicated. h, Quantification of PANX1-mediated ATP release from HEK293T cells transfected with 5 μg control vector, 5 μg wild-type PANX1 (DVVD), 2.5 μg wild-type PANX1 and 2.5 μg PANX1 1-89 , 5 μg caspase resistant full-length PANX1 (AVVA), or 2.5 μg caspase resistant full-length PANX1 and 2.5 μg PANX1 ; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student's t-test. n represents biological replicates in a, b, h, and number of mice in c. Experiments a-d were replicated at least two times with at least two independent cell lines. Experiments e-h are single experiments with biological replicates. Bioluminescent and images are representative of the median. , ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student's t-test. n represents number of mice in a, b, d, f, number of mouse lungs in e and biological replicates in c. Experiments a-c were replicated at least two times with at least two independent cell lines. Therapeutic PANX1 inhibition experiments were performed using differing protocols with two independent triple negative breast cancer cell lines. Bioluminescent and histological images are representative of the median.
